QualityStocks News - International Stem Cell Corp. Congratulates Nobel Prize Winners

Share Article

Company praises efforts of professors and discusses its promising cellular reprogramming technology.

This technology provides an alternative to the existing cellular reprogramming methods and represents an enormous opportunity for ISCO to become a leader in the iPS field.”

QualityStocks would like to highlight International Stem Cell Corporation (OTCBB: ISCO), focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs).

In the company’s news yesterday,

International Stem Cell Corp. applauded Sir John Gurdon and Dr. Shinya Yamanaka for securing the Nobel Prize in Physiology or Medicine. The team’s use of cellular reprogramming to create pluripotent stem cells has led to the development of induced pluripotent stem cells (iPS), which is now a major area of research. However, cellular reprogramming is currently accomplished by inserting genetic material, via a virus or otherwise, which raises serious safety concerns when developing treatments.

ISCO, in comparison, has developed a technology that could enable the creation of a new generation of iPS cells without these safety concerns. Unlike methods requiring the use of viruses or DNA constructs that may integrate into the genome, ISCO’s new method utilizes only proteins which are naturally eliminated once they have served their purpose.

“Overall, our new technology represents a level of control that is much finer than the multiple infections necessary for viral-based systems which cannot be turned off and where the dosage level cannot be modulated,” stated Dr. Ruslan Semechkin, Vice President and head of ISCO’s Research and Development. “Moreover, ISCO’s method can be used not only to reprogram somatic cells to become stem cells, but also transform stem cells into somatic cells. This technology provides an alternative to the existing cellular reprogramming methods and represents an enormous opportunity for ISCO to become a leader in the iPS field.”

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for The QualityStocks Daily Newsletter, please visit http://www.QualityStocks.net

Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Editor
Visit website